Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-IFN alfa-2a to Reduce Relapse in HBeAg-Negative Chronic Hepatitis B (CEASE)
NCT02594293Phase 4Completed
- Sponsor
- Huashan Hospital
- Start
- Oct 2015
- Primary completion
- Sep 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB), sponsored by Huashan Hospital. Started Oct 2015; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02594293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594293.